E. R. Squibb & Sons, Inc.

Georges Road New Brunswick, N.J. 08903 201-545-1300

December 1, 1986

Log ..

Arr. 11 th

Fee C:

Reinitter ... Check Kas

By:

*P4 120 31

よろろ 613C

ЗA

x). Hemle

19:14

Typo : : . . Amend Date Cires & Round 12/31 Date Completed 12_

Ms. J. Johansen U. S. Nuclear Regulatory Commission Region I 531 Park Avenue King of Prussia, PA 19406

Reference License # 29-00139-02

Dear Ms. Johansen:

8706030150

870225

This is a request that E. R. Squibb & Son's radioactive material license number 29-000139-02 be amended to reflect:

- Changes in Squibb's Radiation Safety Committee. Α.
- The inclusion of site limitations and additional bypro-Β. duct materials.
- The addition of byproduct material and changes in site с. limitations for the Clinical Support Laboratory located at the Princeton House, 905 Herrontown Rd., Princeton, New Jersey.
- A. Radiation Safety Committee Changes
 - J. Reinhardt replaces Mr. J. Zelenski as a Radia-1. Mr. tion Safety Committee member.
 - 2. Mr. B. Sueskind has become a member of the committee.
 - 3. Ms. E. Nickoloff, PhD, has become a member of the committee.
 - Dr. G. Gennaro has become a rember of the committee. 4.

Enclosed for your records are the biographical profiles of the new committee members along with an updated listing of the committee.

B. Byproduct Material/Possession Limits

ation in this record was delated

th the Freedom of Information A PLOY/ TOYOV TS

Please amend Squibb's license to finclude the following Byproduct materials.

106573

DEC 2 2 1986

SOUIBB

131J

• Byproduct Material	Chemical or Physical Form	Possession Limits
Yttrium 90	Апу	100 mCi
Yttrium 88	Any	10 mCi
Yttrium 91	Any	10 mCi
Cerium 144	Any	10 mCi
Samarium 153	Any	100 mCi
Rhenium 188	Any	10 mCi

The above materials will be used exclusively in non-human research and development studies.

C. Princeton House - Byproduct Material/Possession Limits

Please amend Squibb's license to reflect an increase of possession limits and the addition of the following byproduct materials for use at the Clinical Support laboratory located at the Princeton House.

Byproduct	Form	Present	Requested
Material		Amount	Increase
Hydrogen 3	Any	2 mCi	10 mCi
Carbon 14	Any	2 mCi	10 mCi
Iodine 125 Iron 59	Any Any Any	2 mCi 2 mCi	10 mCi 10 mCi 10 mCi
Chromium 51	Any	2 mCi	10 mCi

Please include the following Byproduct material for nonhuman use in the Clinical Support laboratories located at the Princeton House.

Byproduct Material	Form	Requested Amount
Phosphorus 32 Rubidium 86 Nickel 63	Any Any Plated Source contained in Electron Capture Detector	10 mCi 10 mCi Not to exceed 15 mCi

Enclosed is a check for \$120.00 to cover the cost of processing the amendment.

Sincerely, D. R. Balkunow Radiation Safety Officer E. R. Squibb & Sons, Inc.

DKB/1d1

ADDENDUM 11

Radiation Safety Committee Membership

- 1. Mr. J. P. Gresh, Committee Chairman, Manager, Training Department.
- 2. Mr. R. Healy, Director, Human Resources.
- 3. Mr. G. Thompson, Manager, Radiodiagnostic Production.
- 4. Dr. E. Eaton, Assistant Associate Corporate Medical Director.
- 5. Dr. M. Loberg, Vice-President and General Manager; Squibb Diagnostics.
- 6. Dr. P. Roets, Manager, Personnel, Industrial Hygiene and Safety.
- 7. Mr. H. Bartlett, Manager, Environmental Control.
- 8. Mr. D. K. Balkunow, Health Physics Department Head, and Radiation Safety Officer.
- 9. Dr. G. Gennaro, Section Head, Radioactive Products.
- 10. Dr. E. Nickoloff, Director, Scientific Information Resources.
- 11. Mr. J. Reinhardt, Director Radiodiagnostics Operations and Productivity.
- 12. Mr. B. Sueskind, Senior Attorney.

D)(6)
The Squibb Institute for Medical Research P.O. Box 191 New Brunswick, NJ 08903 (201) 519-3181
)(6)
Rutgers University. New Brunswick, NJ B.S., Chemistry, (b)(6) State University of New York, Buffalo, NY Ph.D., Chemistry, (b)(6)

- E.R. Squibb & Sons, New Brunswick, NJ Section Head, 1984-Date Senior Research Associate, 1982-1984 Research Associate, 1980-1982

Project development responsibility for 82-Sr/82-Rb radionuclide generator and lyophilized diagnostic agents. Responsible for and supply of clinical radiopharmaceuticals. manufacture Generated proposals for new products and product improvements. testing standards and manufacturing documents. Composed Radioanalytical assay development. Computation of absorbed radiation doses and shielding requirements for products and processes. Radiochemical purity by paper chromatography and purity by gamma spectrometry. Mo-99/Tc-99m radionuclidic generator research. Completed workshops in Time Management; Performance Planning and Appraisal; and Finance and Accounting. Appointed to Division Task Force on Cost Containment and two product-related Task Forces.

- Diagnostic Isotopes, Inc., Bloomfield, NJ Director of Radiopharmaceutical Development, 1977-1979

Scientific Advisor to Regulatory Affairs, Quality Control, and Manufacturing. Process and analytical development for radiopharmaceuticals (e.g. Indium oxine [111-In] and Selenomethionine [75-Se]).

- Memorial Sloan-Kettering Institute, New York, NY Research Scientist, 1975

Attempted radiofluorination (18-F) of estradiol as in-vivo radiotracer.

Ramapo College of New Jersey, Mahwah, NJ Assistant Professor of Chemistry : 1972-1977

Developed Courses in Chemistry for Liberal Arts Majors; General Chemistry Physical Chemistry; and Application of Radiation and Radioisotopes in Diverse Disciplines Served as Program Coordinator for Chemistry, Chairman of Faculty Assembly and Personnel Committee for School of Theoretical and Applied Science. Secured NRC license for institution and served as Radiation Safety Officer & Granted Tenure in 1975.

Texas A&M University, College Station, TX Research Associate, 1971-1972

Postdoctoral research and laboratory management. Responsible for implementing program in hot atom chemistry of phosphorus and silicon. Cyclotron production of radioisotopes. Extensive use of vacuum techniques and radio-gas chromatography.

State University of New York, Buffalo, NY are e estra 🖊

Research Assistant, 1967-70 Teaching Assistant, 1965-67

Reactor production of radioisotopes. Radioanalytical techniques. Radio-gas chromatography.

PROFESSIONAL AFFILIATIONS

American Chemical Society, Division of Nuclear Chemistry and

Society of Nuclear Medicine, Radiopharmaceutical Science Council Journal of Nuclear Medicine, Manuscript Reviewer

BIBLIOGRAPHY

GENNARO GP: Hot Atom Chemistry of Organic Halides in Solution, Ph.D. Thesis, State University of New York at Buffalo, 1970; Diss. Abstr. Int., 31, 5247B (1971).

GENNARO GP and COLLINS KE: Solution Phase Cerenkov Counting of 80g-Br and 80m-Br in the Presence of 82-Br., J. Radioanal. Chem., 5, 387-389 (1970) .

GENNARO GP and COLLINS KE: Geminate Retention from Nuclear Isomeric Transition and Radiative Thermal Neutron Capture in Carbon Tetrabromide-Ethanol Solutions, J. Phys. Chem., 74, 3094-3101 (1970).

DANIEL SHE GENNARO GP, RANCK KM, and TANG YN: Recoil Tritium Reactions with Hexamethyldisilane in the Gas Phase, J. Phys. Chem., 76, 1249-1254 (1972).

COLLINS KE: COLLINS CH, KAPAUAN PA, NAVARRO QO, KAPAUAN AF, and GENNARO GP: The Half-life of Bromine 80g, J. Inorg. Nucl. Chem., 34, 2971-2973 (1972)

34, 2971-2973 (1972) TANG YN, GENNARO GP, and SU YY: Direct Evidence for the Reaction of Monomeric Silicon Difluoride with 1,3-Butadiene, J. Amer. Chem. Soc., 94, 4355-4357 (1972)

GENNARO GP and TANG YN: Gas Phase Recoil Phosphorus Reactions I: Complete and Partial Retention of Bonds in PF5, J. Inorg. Nucl. Chem., 35, 3087-3094 (1973).

GENNARO GP and TANG YN: Gas Phase Recoil Phosphorus Reactions II: A Detailed Study of Pressure and Scavenger Effects, <u>J. Inorg.</u> <u>Nucl. Chem.</u>, <u>36</u>, 259-262 (1974).

GENNARO GP, SU YY, ZECK OF, DANIEL SH, and TANG YN: The Addition of Triplet and Singlet Silylene to 1,3-Butadiene, <u>J. Chem. Soc.</u>, <u>Chem. Commun.</u>, 637-638 (1973).

ZECK OF, GENNARO GP, and TANG YN: Relative Efficiencies of Hydrogen Abstraction by Recoil Phosphorus Atoms, J. Chem. Soc., Chem. Commun., 52-53 (1974).

ZECK OF, SU YY, GENNARO GP, and TANG YN: The Ground Electronic State of Silylene, <u>J. Amer. Chem. Soc.</u>, <u>96</u>, 5967-5973 (1974).

ZECK OF, GENNARO GP, and TANG YN: Gas Phase Recoil Phosphorus Reactions III: Systematic Study of Hydrogen Abstraction Reactions, J. Amer. Chem. Soc., 97, 4498-4503 (1975).

ZECK OF, SU YY, GENNARO GP, and TANGOYN: Effect of Additives on the Reaction of Monomeric Silicon Diffuoride with 1,3-Butadiene, J. Amer. Chem. Soc., 98, 3474-3477 (1976).

ZECK OF, FERRIERI RA, COPP CA, GENNARO GP and TANG YN: Gas Phase Recoil Phosphorus Reactions IV: Effect of Moderators on the Abstraction Reactions, J. Inorg. Nucl. Chem., 41, 785-789 (1979).

REEVES RJ, CARROLL RT, and GENNARO GP: Titration of Phytic Acid, Talanta, 26, 1033-1034 (1979).

Reas

Min.

CT.

TOSCH KW, HORNICK JS, and GENNARO GP: Radiochromatography of Indium (111-In) Oxine, <u>J. Radioanal.</u> <u>Chem.</u>, <u>53</u>, 345-349 (1979).

NEIRINCKX RD, KRONAUGE JF, GENNARO GP, and LOBERG MD: Evaluation of Inorganic Adsorbents for the Rubidium-82 Generator: I. Hydrous SnO₂, J. Nucl. Med., 23, 245-249 (1982).

GENNARO GP, WEDEKING P, HANEY TA, NEIRINCKX RD, and LOBERG MD: An Evaluation of Analytical Techniques Used in the Development of Radionuclide Generators, J. Labelled Compounds Radiopharm., 19, 1533-1534 (1982).

> (4) (行利)

NEIRINCKX RD, COCHAVI S, GENNARO GP, LOBERG MD, KRONAUGE JF, GOLDSMITH SL, and O'BRIEN HA: Application of a Commercial Sr-82/Rb-82 Generator for Heart and Kidney Imaging, <u>Nucl. Med.</u> <u>Biol. Adv., Proc. World Cong. 3rd</u>, 1, 613-616, 1982 (Pub. 1983), Pergamon: Oxford, U.K.

Sector Construction

GENNARO GP, NEIRINCKX RD, BERGNER B, et. al.: A Radionuclide Generator and Infusion System for the Delivery of Pharmaceutical Quality Rb-82, in "Radionuclide Generators: New Systems for Nuclear Medicine Applications," American Chemical Society, Washington, DC, 1984.

BERGNER BC, LOBERG MD, and GENNARO GP: Rubidium-82 Infusion System, in "Single Photon Ultrashort-lived Radionuclides," United States Department of Energy, CONF-830504, Washington, DC, 1985.

GENNARO GP, BERGNER BC, HANEY PS, et. al.: Radioanalysis of 82-Rb Generator Eluates, Appl. Radiat. Isotopes, in press.

DHAWAN V and GENNARO GP: An Alternative Approach to On-Line Monitoring of Elution Profiles of Rb-82 for Radioassay/Radiation Dosimetry, J. Nucl. Med., 27, 1038 (1986).

GENNARO GP and HANEY PS: Strontium-82/Rubidium-82 Generator, US Patent 4,597,951, July 1, 1986.

1-3 - 7aP

Section of the section of the


HANEY PS and GENNARO GP: Hydroxylapatite-based 82-Sr/82-Rb Generator, J. Labelled Compounds Radiopharm., in press.

ABSTRACTS AND PRESENTATIONS

American Chemical Society Boston, 1972 (2) New York, 1972 (2) Dallas, 1973 Los Angeles, 1974 Houston, 1974 (Southwest Regional) Chicago, 1975 Seattle, 1983

Chemical Institute of Canada Toronto, 1967

International Hot Atom Chemistry Symposia Cambridge, England, 1969 Julich, West Germany, 1973 (2) Spa, Belgium, 1975



CURAICULUM VITAE

EILEEN NICKOLOFF, Ph.D.

PROFESSIONAL EXPERIENCE:

9/85-Present Director, Scientific Information Resources

Squibb Institute for Medical Research Princeton, N.J.

Responsible for ROD Computer Group (Scientic Information Systems) which handles all scientific computer functions for ROD. Named ROD Coordinator for new building to be built on Princeton site. Responsbile for Science Information at Squibb, which includes all library O literature searching functions.

ふいたい

9/84-9/85

Administrative Director, Diagnostic R&D

Squibb Institute for Medical Research New Brunswick, N.J.

Responsible for all budgetary, personnel and scientific administrative functions including computer networking for a staff of 65 scientists.

1/80-9/85

Director, Clinical Assay R&D

Squibb Institute for Medical Research New Brunswick, N.J.

Brought 13 immunoassays to market, including all research, development, validation, troubleshooting, antibody production, clinical studies and product coordination. Developed research assays for inhouse use, including drugs, prostaglandins, bradykinin and complement factors. 1974-1980

Director, In-Ditro Laboratory **Director**, Radiopharmacy The Johns Hopkins Hospital

Baltimorc, MD

Increased the number of in-vitro tests performed from 200 to 2500/month in four years. Supervised preparation and quality control testing for all clinical and research imaging agents.

なきませんでいたのできょう

1971-1974

Clinical Chemist

Harrisburg Hospital

Horrisburg, PR

Directed all clinical chemistry, dialysis, toxicology and urinalysis functions.

1970-1971

Supervisor, Core Laboratory

Thorndike Laboratory, Harvard Medical Unit

Boston City Hospital, Boston, MA

Directed Core Laboratory, setting up research assays. Validated assays for use in measuring blood changes during transcendental meditation.

BOARD CERTIFICATION:

American Board of Clinical Chemistry, 1976

PROFESSIONAL	
RFFILIATIONS:	

うち、夢 御殿をを いきまたいため ちょうちん

A CONTRACTOR OF A CONTRACTOR O

American Association for Clinical Chemistry President, New Jersey Chapter, 1983-4 **Clinical Ligand Assay Society** President, National, 1979-80

General Chairman, National Meeting, 1979, 1982

Society of Nuclear Medicine

Co-Vice Chairman RIA, 1979 National Meeting

EDUCATION:

St. Joseph's College, Brooklyn, N.Y. **B.A., Chemistry** (b)(6)

University of New Hampshire, Durham, N.H. Ph.D., Organic Chemistry, (b)(6)

PUBLICATIONS:

10 Book Chapters 12 Journal articles 30 published abstracts

	SQUIE					
•						
•	то	D.K. Balkunc	w.		DATE	November 6, 1986
	FROM	B.R. Sueskin	xđ		COPY TO	
	SUBJECT	BIOGRAPHIC P RADIATION SA	PROFILE FETY COMMITTEE			
		nse to your m d biographic	remo dated Octob profile.	œr 31, 1986,	I am pro	viding the
	1.	Company Empl	loyment History:	1		
		Special Cons Senior Attor	sultant: May, 1 mey: Januar	1985 - Decemb ry, 1986 to d		
		advice on le	ities include pr egal and corpora safety matters.	coviding lega ate matters,	l represe including	ntation and environmental,
	2.	Education: BA, Queens C JD, New York	College, (b)(6) University, (b)((6) (14.5. (14.5.)		
	3.	Special Educ	cation (if neces			
		Not necessar	У•			
	4.	Personal:				
		a. Name: b. Address: (Office)		ration		
		(Home)	(b)(6)			
	Please 1	et me know if	E you need anyth	ing further.		٨
			-			R. SUESKIND

•

. '

•

•

• ~

÷

•

John P. Reinhardt Director, Operations and Productivity Squibb Diagnostics

Education

University of Scranton, BS Biology/Chemistry (b)(6)University of Tennessee, Graduate Studies, Pharmacology (b)(6)

Professional Experience

Analytical Chemist, Quality Control, E. R. Squibb & Sons Jun-Oct 1957 Sales Representative, E. R. Squibb & Sons 1958-1969 *Technical Associate, Nuclear Medicine, E. R. Squibb & Sons 1969-1973 *Training Associate, Nuclear Medicine, E. R. Squibb & Sons 1973-1975 Product Manager, X-Ray Contrast Media, E. R. Squibb & Sons 1975-1979 *Director, Training, E. R. Squibb & Sons 1979-1981 *Product Manager, Nuclear Medicine, Squibb Diagnostics 1981-1983 *Marketing Services Manager, Squibb Diagnostics 1983-1986 *Director, Operations and Productivity, Squibb Diagnostics 1986-Present

Professional Societies

2

and the second second

American Chemical Society 1969-1985 Society of Nuclear Medicine 1969-1986 Society of Nuclear Medicine (Technologist Section)

*During these periods, direct involvement with Health Physics training for sales staff and/or customers.

License Fee Management Branch	5/81
Nuclear Materials Section B Division of Engineering and Technical Programs LICENSE FEE TRANSMITTAL A. <u>REGION</u> 1. <u>APPLICATION ATTACHED</u> Applicant/Licensee: <u>Y.R. Sequebb condension</u> Application Dated: <u>19/1/36</u> Control No.: <u>106573</u> License No.: <u>21. (C.Bin (C)</u> 2. <u>FEE ATTACHED</u> Amount: <u>12(.CC</u> Check No.: <u>STIGUES</u> 3. <u>COMMENTS</u> Signed <u>12(25)</u> B. <u>LICENSE FEE MANAGEMENT BRANCH</u>	
 A. <u>REGION</u> 1. <u>APPLICATION ATTACHED</u> Applicant/Licensee: <u>F.R. Separable condension</u> Application Dated: <u>12/1/36</u> Control No.: <u>106573</u> License No.: <u>21.006573</u> License No.: <u>21.006573</u> Check No.: <u>21.006573</u> Amount: <u>120.000</u> Check No.: <u>201415</u> 3. <u>COMMENTS</u> Signed <u>D.Couvertine</u> Date <u>12/23/200</u> B. <u>LICENSE FEE MANAGEMENT BRANCH</u> SINCE STREED	
1. <u>APPLICATION ATTACHED</u> Applicant/Licensee: <u>F.R. Sepul.bb condension</u> Application Dated: <u>13/1/34</u> Control No.: <u>106573</u> License No.: <u>31. (C.BG.C.)</u> 2. <u>FEE ATTACHED</u> Amount: <u>ADC.CC</u> Check No.: <u>SD1445</u> 3. <u>COMMENTS</u> 3. <u>COMMENTS</u> B. <u>LICENSE FEE MANAGEMENT BRANCH</u>	
Applicant/Licensee: $f_{R} \approx 13/1/32$ Application Dated: $13/1/32$ Control No.: 106573 License No.: 21.00573 License No.: 21.00126 Amount: $13/126$ Check No.: 537445 3. <u>COMMENTS</u> Signed $13/356$ B. <u>LICENSE FEE MANAGEMENT BRANCH</u>	
Application Dated: $12/1/4$ Control No.: 106573 License No.: $21 \cdot (C.136)$ 2.FEE ATTACHEDAmount: $120 \cdot (C.136)$ Check No.: 351445 3.COMMENTSSigned D.C.INCTIDate 12355 B. LICENSE FEE MANAGEMENT BRANCH	
Control No.: <u>106573</u> License No.: <u>21. (C. 1261)</u> 2. <u>FEE ATTACHED</u> Amount: <u>21. (C. 1261)</u> Amount: <u>21. (C. 1261)</u> (Check No.: <u>25.74475</u> 3. <u>COMMENTS</u> 3. <u>COMMENTS</u> Signed <u>D. C. WARTI</u> Date <u>12</u> 255 B. <u>LICENSE FEE MANAGEMENT BRANCH</u>	
License No.: <u>Die Comparente Stand</u> 2. <u>FEE ATTACHED</u> Amount: <u>Die CC</u> Check No.: <u>STUP</u> 3. <u>COMMENTS</u> 3. <u>COMMENTS</u> B. <u>LICENSE FEE MANAGEMENT BRANCH</u>	
2. <u>FEE ATTACHED</u> Amount: <u>Pac.cc</u> Check No.: <u>STULTS</u> 3. <u>COMMENTS</u> Signed <u>December 12</u> Date <u>12</u> B. <u>LICENSE FEE MANAGEMENT BRANCH</u>	
Amount: <u>SST445</u> Check No.: <u>SST445</u> 3. <u>COMMENTS</u> Signed <u>D.Competit</u> Date <u>12</u> B. <u>LICENSE FEE MANAGEMENT BRANCH</u>	
Check No.: <u>SST4415</u> 3. <u>COMMENTS</u> Signed <u>D.C.WACT1</u> Date <u>12</u> 23	
Check No.: <u>SST4415</u> 3. <u>COMMENTS</u> Signed <u>D.C.WACT1</u> Date <u>12</u> 23	
3. <u>COMMENTS</u> Signed <u>P. Comments</u> Date <u>12</u> B. <u>LICENSE FEE MANAGEMENT BRANCH</u>	
B. LICENSE FEE MANAGEMENT BRANCH	
B. LICENSE FEE MANAGEMENT BRANCH	
B. LICENSE FEE MANAGEMENT BRANCH	Store K
1. Fee Category and Amount: $\underline{>}$ $\underline{>}$ $\underline{>}$	•
)_L
2. Correct Fee Paid. Application may be processed for:	
Amendment	
Renewal	
License	A
Signed Stinut	. Um
. Date (12/3//5	(, cap
	6 1 Ca
ON I FORM 213 CH 1983)	<u>u, luj</u> 6
	$\frac{c_1 \cdot c_2}{c_1}$

Note To: License Fee Management Section, ADM Region From: Subject: VOIDED APPLICATION Control Number 106648 Applicant F.R. Squibb + Sons Tix Date Volded 2/25/87 Reason for Void: đ_a. A Control No. 1066-18 done with control No. 106573 after sprinte _____ ę.... Brondo Platelick 2/25/87 Signature Attachment: Official Record Copy of Voided Action B., . DKLFM N. referrise mL